{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:43Z","timestamp":1787003503928,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1038\/s41591-023-02544-9","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:02:39Z","timestamp":1697457759000},"page":"2458-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade"],"prefix":"10.1038","volume":"29","author":[{"given":"Emily C.","family":"Harrold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-2405","authenticated-orcid":false,"given":"Michael B.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1594-4827","authenticated-orcid":false,"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1188-350X","authenticated-orcid":false,"given":"Henry","family":"Walch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5042-5651","authenticated-orcid":false,"given":"Yelena","family":"Kemel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergus","family":"Keane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H.","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zalak","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Borio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Reidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avni","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Y.","family":"Janjigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9027-2891","authenticated-orcid":false,"given":"Yonina R.","family":"Murciano-Goroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4786-7408","authenticated-orcid":false,"given":"Maria I.","family":"Carlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Latham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying L.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-2247","authenticated-orcid":false,"given":"David","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold J.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-7984","authenticated-orcid":false,"given":"Martin R.","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-0237","authenticated-orcid":false,"given":"Chad","family":"Vanderbilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Mandelker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-4919","authenticated-orcid":false,"given":"Chaitanya","family":"Bandlamudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3882-5000","authenticated-orcid":false,"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6614-802X","authenticated-orcid":false,"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Saltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4351-2511","authenticated-orcid":false,"given":"Jinru","family":"Shia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7079-8914","authenticated-orcid":false,"suffix":"Jr.","given":"Luis A.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6985-2864","authenticated-orcid":false,"given":"Zsofia K.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2544_CR1","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1200\/JCO.2011.39.5590","volume":"30","author":"AK Win","year":"2012","unstructured":"Win, A. K. et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J. Clin. Oncol. 30, 958\u2013964 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2544_CR2","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.18.00283","volume":"37","author":"A Latham","year":"2019","unstructured":"Latham, A. et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J. Clin. Oncol. 37, 286\u2013295 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2544_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409\u2013413 (2017).","journal-title":"Science"},{"key":"2544_CR4","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","volume":"386","author":"A Cercek","year":"2022","unstructured":"Cercek, A. et al. PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363\u20132376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2544_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"2544_CR6","doi-asserted-by":"publisher","first-page":"100044","DOI":"10.1016\/j.esmoop.2020.100044","volume":"6","author":"P Heudel","year":"2021","unstructured":"Heudel, P. et al. Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. ESMO Open 6, 100044 (2021).","journal-title":"ESMO Open"},{"key":"2544_CR7","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nm.4333","volume":"23","author":"A Zehir","year":"2017","unstructured":"Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 23, 703\u2013173 (2017).","journal-title":"Nat. Med."},{"key":"2544_CR8","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.chom.2020.03.005","volume":"27","author":"Yan","year":"2020","unstructured":"Yan et al. Structure of the mucosal and stool microbiome in Lynch syndrome. Cell Host Microbe 27, 585\u2013600 (2020).","journal-title":"Cell Host Microbe"},{"key":"2544_CR9","doi-asserted-by":"crossref","unstructured":"Del Carmen, G et al. Colorectal surveillance outcomes from an institutional longitudinal cohort of lynch syndrome carriers. Front. Oncol. 13, 1146825.","DOI":"10.3389\/fonc.2023.1146825"},{"key":"2544_CR10","doi-asserted-by":"crossref","unstructured":"Middha, S. et al. Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis. Oncol. 2017, PO.17.00084 (2017).","DOI":"10.1200\/PO.17.00084"},{"key":"2544_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/gutjnl-2016-311403","volume":"66","author":"P Moller","year":"2017","unstructured":"Moller, P. et al. Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database. Gut 66, 1657\u20131664 (2017).","journal-title":"Gut"},{"key":"2544_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1126\/science.aau0447","volume":"364","author":"R Mandal","year":"2019","unstructured":"Mandal, R. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 364, 485\u2013491 (2019).","journal-title":"Science"},{"key":"2544_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ccell.2022.12.003","volume":"41","author":"V Amodio","year":"2022","unstructured":"Amodio, V. et al. Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance. Cancer Cell 41, 196\u2013209 (2022).","journal-title":"Cancer Cell"},{"key":"2544_CR14","doi-asserted-by":"publisher","unstructured":"Westcott, P. M. K. et al. Mismatch repair deficiency is not sufficient to increase tumor immunogenicity. Nat Genet (2023). https:\/\/doi.org\/10.1038\/s41588-023-01499-4","DOI":"10.1038\/s41588-023-01499-4"},{"key":"2544_CR15","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ijc.33224","volume":"148","author":"A Ahadova","year":"2021","unstructured":"Ahadova, A. et al. The \u2018unnatural\u2019 history of colorectal cancer in Lynch syndrome: lessons from colonoscopy surveillance. Int. J. Cancer 148, 800\u2013811 (2021).","journal-title":"Int. J. Cancer"},{"key":"2544_CR16","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S1470-2045(12)70109-2","volume":"13","author":"M Kloor","year":"2012","unstructured":"Kloor, M. et al. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study. Lancet Oncol. 13, 598\u2013606 (2012).","journal-title":"Lancet Oncol."},{"key":"2544_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2023.03.007","volume":"165","author":"A Ahadova","year":"2023","unstructured":"Ahadova, A. et al. A \u2018two-in-one hit\u2019 model of shortcut carcinogenesis in MLH1 Lynch syndrome carriers. Gastroenterology 165, 267\u2013270 (2023).","journal-title":"Gastroenterology"},{"key":"2544_CR18","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaoncol.2018.1482","volume":"4","author":"K Chang","year":"2018","unstructured":"Chang, K. et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol. 4, 1085\u20131092 (2018).","journal-title":"JAMA Oncol."},{"key":"2544_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1158\/1940-6207.CAPR-11-0519","volume":"5","author":"MB Yurgelun","year":"2012","unstructured":"Yurgelun, M. B. et al. Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev. Res. 5, 574\u2013582 (2012).","journal-title":"Cancer Prev. Res."},{"key":"2544_CR20","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.cell.2020.11.004","volume":"183","author":"V Roudko","year":"2020","unstructured":"Roudko, V. et al. Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell 183, 1634\u20131649 (2020).","journal-title":"Cell"},{"key":"2544_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-017-0271-4","volume":"10","author":"DT Cheng","year":"2017","unstructured":"Cheng, D. T. et al. Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Med. Genomics 10, 33 (2017).","journal-title":"BMC Med. Genomics"},{"key":"2544_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng, D. T. et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J. Mol. Diagn. 17, 251\u2013264 (2015).","journal-title":"J. Mol. Diagn."},{"key":"2544_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/his.14271","volume":"78","author":"J Shia","year":"2021","unstructured":"Shia, J. The diversity of tumours with microsatellite instability: molecular mechanisms and impact upon microsatellite instability testing and mismatch repair protein immunohistochemistry. Histopathology 78, 485\u2013497 (2021).","journal-title":"Histopathology"},{"key":"2544_CR24","doi-asserted-by":"publisher","unstructured":"Ziegler, J. et al. MiMSI\u2014a deep multiple instance learning framework improves microsatellite instability detection from tumor next-generation sequencing. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2020.09.16.299925 (2020).","DOI":"10.1101\/2020.09.16.299925"},{"key":"2544_CR25","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"2544_CR26","doi-asserted-by":"publisher","first-page":"e1007757","DOI":"10.1371\/journal.pcbi.1007757","volume":"16","author":"S Paul","year":"2020","unstructured":"Paul, S. et al. Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system. PLoS Comput. Biol. 16, e1007757 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"2544_CR27","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nbt.3344","volume":"33","author":"SA Shukla","year":"2015","unstructured":"Shukla, S. A. et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat. Biotechnol. 33, 1152\u20131158 (2015).","journal-title":"Nat. Biotechnol."},{"key":"2544_CR28","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).","journal-title":"Nucleic Acids Res."},{"key":"2544_CR29","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259\u20131271 (2017).","journal-title":"Cell"},{"key":"2544_CR30","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1200\/JCO.2022.40.16_suppl.10505","volume":"40","author":"E Harrold","year":"2022","unstructured":"Harrold, E. et al. The frequency of second primary malignancies and colonic polyps in Lynch syndrome with MSI tumors following immune checkpoint blockade. J. Clin. Oncol. 40, 10505\u201310505 (2022).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02544-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02544-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02544-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T12:07:53Z","timestamp":1697458073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02544-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2544"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02544-9","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"19 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C.H. has received funding from the Conquer Cancer ASCO Foundation. She also served as a consultant to Pfizer Ireland on one occasion in 2021. She reports education grants from Merck and Amgen to attend GI ASCO in 2020. B.R. serves as a consultant for Neophore and has a patent: \u2018Methods and composition for cancer immunotherapy\u2019. F.K. has received funding from the Conquer Cancer ASCO Foundation. A.C. serves as a consultant for Bayer, GlaxoSmithKline, Janssen Biotech, Merck and Seagen and receives research funding from GlaxoSmithKline, Inspirna and Seagen. R.Y. serves as a consultant for Array BioPharma\/Pfizer, Amgen, Mirati Therapeutics and Natera and receives research funding to her institution from Pfizer, Boehringer Ingelheim, Mirati Therapeutics and Daiichi Sankyo. D.R. is an uncompensated advisor\/steering committee member and receives research support from Janssen, AstraZeneca, Bayer, Myovant, Genentech, Promontory and Bristol Myers Squibb\/Celgene. N.H.S. serves as a consultant for ABL Bio, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Immunocore, Novartis, Psioxus, Puretech, Revitope, Roche\/Genentech and Numab and receives grant\/contracts from AstraZeneca, Bristol Myers Squibb, Immunocore, Merck, Pfizer, Puretech, Regeneron Pharmaceuticals, Roche\/Genentech and Agenus. E.M.O. receives research from Genentech\/Roche, Bristol Myers Squibb\/Celgene, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute and NIH\/NCI and serves as a consultant for CytomX Therapeutics (Data and Safety Monitoring Board (DSMB)), Rafael Therapeutics (DSMB), Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, IDEAYA, Silenseed, Novartis, AstraZeneca, BioSapien, Astellas, Thetis, Autem, Novocure, Neogene, Bristol Myers Squibb, ZielBio, Merus, Tempus and Fibrogen. An immediate family member serves as a consultant for Agios, Genentech\/Roche, Eisai and Servier. D.R. receives research funds from Merck, Novartis and Ipsen and is on the scientific advisory board for Chiasma, Novartis and Advanced Accelerator Applications. Y.Y.J. receives research funding from Bayer, Bristol Myers Squibb, Cycle for Survival, the US Department of Defense, Eli Lilly, Fred\u2019s Team, Genentech\/Roche, Merck, NCI and RGENIX and serves on the advisory boards\/is a consultant for Amerisource Bergen, Arcus Biosciences, AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Geneos Therapeutics, GlaxoSmithKline, Imedex, Imugene, Lynx Health, Merck, Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Paradigm Medical Communications, PeerView Institute, Pfizer, Research to Practice, RGENIX, Seagen, Silverback Therapeutics and Zymeworks and has stock options in RGENIX. Y.R.M.-G. reports travel, accommodation and expenses from AstraZeneca and Loxo Oncology\/Eli Lilly. She acknowledges honoraria from Virology Education and Projects in Knowledge (for a CME program funded by an educational grant from Amgen). She also acknowledges associated research funding to the institution from Mirati Therapetuics, Loxo Oncology\/Eli Lilly, Elucida Oncology, Taiho Oncology, Hengrui USA, Jiangsu Hengrui Pharmaceuticals, Luzsana Biotechnology, Endeavor Biomedicines and AbbVie. She is an employee of Memorial Sloan Kettering Cancer Center, which has an institutional interest in Elucida. She acknowledges royalties from Rutgers University Press and Wolters Kluwer. She acknowledges food and beverages from Endeavor Biomedicines. Y.R.M.-G. also acknowledges receipt of training through an institutional K30 grant from the NIH (CTSA UL1TR00457). She has received funding from a Kristina M. Day Young Investigator Award from Conquer Cancer and the ASCO Foundation, endowed by Dr. Charles M. Baum and Carol A. Baum. She is also funded by the Fiona and Stanley Druckenmiller Center for Lung Cancer Research, the Andrew Sabin Family Foundation, the Society for MSK and a Paul Calabresi Career Development Award for Clinical Oncology (NIH\/NCI K12 CA184746). Y.L.L. reports research funding from AstraZeneca, GlaxoSmithKline and Repare Therapeutics outside this work. J.E.R. has received research support for clinical trials from Bayer, Seagen, Astellas, AstraZeneca and Roche\/Genentech. He has served as an advisor or consultant to Bayer, Seagen, Astellas, AstraZeneca, Roche\/Genentech, Bristol Myers Squibb, Merck, Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Mirati, EMD Serono, Gilead, Alligator Biosciences, Eli Lilly, Tyra Biosciences, Infinity, IMVax, Aadi, Century Therapeutics, Emergence Therapeutics and Hengrui. M.R.W. participates in Precisa online tumor board and is editor of Colorectal Section UpToDate. A.M.R. serves as a consultant for Regeneron, Evolve CME, Almiral, Mavig, Dynamed, Canfield Scientific, Evolus, Biofrontera, QuantiaMD, Lam Therapeutics and Cutera. He participated in an Advisory board for AllerganInc. He serves as an advisor to Skinfix and L\u2019Oreal; he is a founder of DAR companies and is on the Board of Skinpass. A.M.R. received research\/study funding from ASLMS: A Ward Memorial Research Grant, Skin Cancer Foundation, Regen, LeoPharma and Biofrontera and serves as Editorial Board: Lasers in Surgery and Medicine, CUTIS, <i>Journal of the American Academy of Dermatology and Dermatologic Surgery<\/i>. He is a Board Member: ASDS, and a Committee Member and\/or Chair: AAD, ASDS and ASLM. A.M.R acknowledges travel support from Merz. K.O. is a founder (uncompenstated, shares not alloted) of AnaNeo Therapeutics. Patents, royalties, other intellectual property: \u2018Diagnosis and treatment of ERCC3-mutant cancer\u2019; inventors: Joseph Vijai, Sabine Topka and Kenneth Offit; US National Stage Patent Application No.: 16\/493,214; filing date: 11 September 2019 (institution). M.F.B. serves as a consultant for Eli Lilly and AstraZeneca and receives research support from Boundless Bio. D.B.S. has served as a consultant for\/received honorarium from Pfizer, Loxo Oncology\/Eli Lilly, Vividion Therapeutics, Scorpion Therapeutics, FORE Therapeutics, Fog Pharma, Elsie Biotechnologies and BridgeBio. L.S. serves as consultant and is a member of the scientific advisory board for Genor Biopharma. J.S. serves as a consultant for Paige AI. L.A.D. is a member of the board of directors of Quest Diagnostics and Epitope. He is a compensated consultant to PetDx, Innovatus CP, Se\u2019er, Delfi, Blackstone, Kinnate and Neophore. L.A.D. is an inventor on multiple licensed patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy. Some of these licenses and relationships are associated with equity or royalty payments to the inventors. He holds equity in Quest Diagnostics, Epitope, PetDx, Se\u2019er, Delfi, Kinnate and Neophore. He divested his equity in Personal Genome Diagnostics to LabCorp in February 2022 and divested his equity in Thrive Earlier Detection to Exact Biosciences in January 2021. His spouse holds equity in Amgen. The terms of all these arrangements are being managed by Memorial Sloan Kettering Cancer Center in accordance with their conflict of interest policy. Z.K.S.\u2019s immediate family member serves as a consultant in ophthalmology for Adverum, Genentech, Neurogene, Novartis, Optos Plc, Outlook Therapeutics and Regeneron outside the submitted work. Z.K.S. serves as an associate editor for <i>JCO Precision Oncology<\/i> and as a section editor for UpToDate. E.C.H., M.B.F., B.R., L.A.D. and Z.K.S. filed a patent application (patent number 63\/578,057) reflecting the findings of this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}